Cerus (CERS) Q2 2024 earnings summary

Executive summary

• Q2 2024 product revenue rose 16% year-over-year to $45.1 million, with H1 revenue up 20% to $83.4 million, driven by strong U.S. platelet sales and full Canadian Blood Services adoption.

• Full-year 2024 product revenue guidance was raised to $175–178 million, reflecting confidence in continued growth and higher expected demand for INTERCEPT Fibrinogen Complex (IFC).

• Net loss narrowed to $5.8 million in Q2 2024 from $13.3 million in Q2 2023, with positive adjusted EBITDA of $0.8 million and positive operating cash flow.

• INTERCEPT Blood System adoption is expanding globally, with increasing recognition of pathogen inactivation's role in blood safety.

• Restructuring and cost controls contributed to lower operating expenses and improved profitability.

Financial highlights

• Q2 2024 product revenue: $45.1 million (up 16% year-over-year); H1 2024 product revenue: $83.4 million (up 20%).

• Q2 2024 government contract revenue: $5.4 million, down from $8.9 million in Q2 2023.

• Q2 2024 product gross profit: $24.7 million, with gross margin stable at 54.7%.

• Q2 2024 operating expenses: $33.9 million, down 19% year-over-year.

• Cash, cash equivalents, and short-term investments at June 30, 2024: $71.2 million.

Outlook and guidance

• Full-year 2024 product revenue guidance raised to $175–178 million; IFC revenue expected at $8–10 million.

• Management expects continued improvements in GAAP net loss and is committed to achieving adjusted EBITDA breakeven for 2024.

• Product gross margin expected to remain consistent with Q2 2024 levels for the rest of the year.

• No significant inventory rebuilds anticipated; growth driven by increased adoption and demand.

• Available cash and investments expected to be sufficient for at least the next 12 months.